Those living in Scotland with the rare blood cancer polycythaemia vera (PV) will soon gain access to a new treatment option on the NHS after cost regulators approved funding for Novartis’ Jakavi (ruxolitinib). The drug can be used on the NHS to treat adults with polycythaemia vera (PV) who are resistant to, or intolerant of, hydroxyurea
Roche’s early stage breast cancer treatment, Pertuzumab, hasbeen accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland. The drug is used in combination with Trastuzumab and chemotherapy to treat a particular type of early stage breast cancer before surgery, and was accepted after consideration through SMC’s Patient and Clinician Engagement
Patients who have received at least one prior therapy for multiple myeloma in Scotland will soon have access to Amgen’s Kyprolis in combination with dexamethasone through the NHS, following a recommendation by the Scottish Medicines Consortium (SMC). This is a big achievement for the American biopharma, as the drug is the first and only proteasome
The Scottish Medicines Consortium (SMC) have issued final advice recommending the approval of Boehringer Ingelheim’s Trajenta with insulin to treat adults with type 2 diabetes to improve glycaemic control. The recommendation follows a Health Technology Appraisal accepting Trajenta (linagliptin) for treatment in combination with insulin with or without metformin, when insulin alone, with diet and
The Scottish Medicines Consortium (SMC) has announced their latest set of recommendations approving regulatory submissions for Novartis and ThromboGenics’ eye therapy Jetrea and Roche’s RoActemra. The SMC have also announced rejections for the chronic obstructive pulmonary disease (COPD) drugs submitted for approval by Boehringer Ingelheim and GlaxoSmithKline (GSK).
Patients with diabetes in Scotland have gained routine access to AstraZeneca/ Bristol-Myers Squibb’s Forxiga on the UK National Health Service (NHS) after it was considered cost-effective by the Scottish Medicines Consortium (SMC). The SMC have dispensed guidance to healthcare professionals approving the use of the first-in-class drug Forxiga (dapagliflozin) in adults with type 2 diabetes
The Scottish Medicines Consortium (SMC) has approved Celgene’s Vidaza (azacitidine) in patients with advanced myelodysplastic syndromes (MDS). The SMC’s decision takes into account benefits of a new patient access scheme for Vidaza, which is the only drug available in Europe for advanced myelodysplastic syndrome, a rare but debilitating disease which affects around 2,150 people in
